Genes & Diseases· 2016Q1· Review
Temozolomide resistance in glioblastoma multiforme
- 1,170citations
- Q1SCImago
- 2016year
Short summary
Glioblastoma cells develop resistance to temozolomide (TMZ) through mechanisms like MGMT expression or DNA repair pathway deficiencies, with intrinsic and acquired resistance characteristics not yet systematically compared.
AI-generated from the title and abstract; the full text is not read.
Key points
- Temozolomide (TMZ) resistance in glioblastoma (GBM) is often linked to MGMT expression or impaired DNA repair.
- Both naturally occurring and acquired TMZ-resistant GBM cell lines are utilized in research.
- A systematic comparison of intrinsic versus adaptive TMZ resistance in GBM cells is lacking.
- The review consolidates information on resistance mechanisms and potential treatments for TMZ-resistant GBM.
AI-generated from the title and abstract; the full text is not read.
Abstract
-methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been developed for use in experiments designed to define the mechanism of TMZ resistance and the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive TMZ resistant GBM cells have not been systemically compared. This article reviews the characteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell lines. It also summarizes potential treatment options for TMZ resistant GBMs.
The authors' abstract, as published at the source. Genes & Diseases, 2016 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Genetics (Medicine)
GeneticsMedicine